TITLE

ASSOCIATION OF EPIDERMAL GROTH FACTOR MODULE CONTAINIG MUCIN LIKE HORMONE RECETOR 3 (EMR3) MUTATION WITH SUSCEPTIBILITY AND PHENOTYPE OF CROHN'S DISEASE

AUTHOR(S)
Yang, X.; Ahamd, T.; Low, J.; Jewell, D. P.; Zhang, L.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Linkage of Crohn's disease (CD) to chromosome 19p13 has been identified in a Canadian population with inflammatory bowel's disease (IBD) and confirmed in British Caucasians. Epidermal Growth Factor Module, containing Mucin like hormone receptor (EMR3) maps to this region, belongs to a class B seven-span trans-membrane (TM7) receptor Family,and displays a predominantly leukocyte restricted expression pattern, with highest levels in neutrophils, monocytes, and macrophages. It may play a role in myeloid-myeloid interactions during immune and inflammatory responses. Authors postulate that EMR3 is a good positional and also a functional candidate gene for IBD. EMR3 may be a susceptibly gene for CD, independent of CARD 15/N002. The biological significance of its mutations in immunopathogenesis of CD needs to be investigated.
ACCESSION #
13218827

 

Related Articles

  • Nutrigenomika/nutrigenetyka w leczeniu nieswoistych zapalen jelit. Sadakierska-Chudy, Anna // Gastroenterologia Polska / Gastroenterology;2010, Vol. 17 Issue 1, p53 

    Nutrigenomics/nutrigenetics is a developing field that deals with the interplay between the genome, gene polymorphisms, and dietary components. The pathogenesis of inflammatory bowel disease (IBD) may result in part from genetic polymorphisms that regulate innate and adaptive immune responses as...

  • Role of Antimicrobial Peptides in Inflammatory Bowel Disease. Otte, Jan-Michel; Vordenbäumen, Stefan // Polymers (20734360);Dec2011, Vol. 3 Issue 4, p2010 

    Inflammatory bowel diseases (IBD) are characterized by a chronic relapsing inflammation of the gastrointestinal mucosa. The etiology and pathogenesis of these disorders such as Crohn's disease and ulcerative colitis are incompletely understood. Recently, antimicrobial peptides, which are...

  • Adenosine: An immune modulator of inflammatory bowel diseases. Ye, Jeff Huaqing; Rajendran, Vazhaikkurichi M.; Andoh, Akira; Cario, Elke // World Journal of Gastroenterology;9/28/2009, Vol. 15 Issue 36, p4491 

    Inflammatory bowel disease (IBD) is a common and lifelong disabling gastrointestinal disease. Emerging treatments are being developed to target inflammatory cytokines which initiate and perpetuate the immune response. Adenosine is an important modulator of inflammation and its anti-inflammatory...

  • Don't Let Inflammatory Bowel Disease Restrict Your Activities.  // Women's Health Advisor;Aug2014, Vol. 18 Issue 8, p5 

    The article discusses the types, diagnosis and treatment of inflammatory bowel disease (IBD). Topics discussed include types of IBD such as ulcerative colitis and crohn's disease, diagnosing IBD by performing a biopsy of tissue taken from digestive tract and prevention of white blood cells by...

  • LOCALISATION OF EOSINOPHILS TO DIFFERENT SUBSPECIES OF NERVES IN INFLAMMATORY BOWEL DISEASE. Smyth, C. M.; Woods, S.; Thornton, M.; O'Grady, A.; Gleich, G. J.; Murray, F. E.; Costello, R. W. // Gut;Apr2004 Supplement 3, Vol. 53, pA2 

    The role of the eosinophil, which is a common inflammatory cell in inflamed gastrointestinal mucosa in inflammatory bowel disease (IBD) is uncertain. Many of the symptoms of IBD are due to neural dysregulation, including increased mucous production and dysmotilily. Authors hypothesised that an...

  • sulfasalazine. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p721 

    An encyclopedia entry for "sulfasalazine" is presented. It is a disease-modifying antirheumatic drug that is also used to relieve intestinal inflammation in Crohn's disease and ulcerative colitis. Side effects of the drug include aplastic anaemia, and reduction in white blood cells and...

  • Current Therapeutic Approaches in Inflammatory Bowel Disease. Sohrabpour, Amir Ali; Malekzadeh, Reza; Keshavarzian, Ali // Current Pharmaceutical Design;11/28/2010, Vol. 16 Issue 33, p3668 

    No abstract available.

  • Use of a Screening Tool to Determine Nonadherent Behavior in Inflammatory Bowel Disease. Kane, Sunanda; Becker, Brenda; Harmsen, W. Scott; Kurian, Ashok; Morisky, Donald E; Zinsmeister, Alan R // American Journal of Gastroenterology;Feb2012, Vol. 107 Issue 2, p154 

    OBJECTIVES:Nonadherence is an issue in the management of inflammatory bowel disease (IBD), and no validated screening tool is available. We aimed to determine whether scores from a self-reported adherence survey correlated with pharmacy refill data as a reliable measure of medication...

  • Connecting the dost from Toll-like receptors to innate immune cells and inflammatory bowel disease. Boone, David L.; Ma, Averil // Journal of Clinical Investigation;5/1/2003, Vol. 111 Issue 9, p1284 

    Addresses the approaches that may provide novel therapeutic targets for the treatment of inflammatory bowel diseases. Negative regulators of inflammation; Physiological importance of IL-10 receptor; First step in initiating immune responses.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics